300497 Jiangxi Fushine Pharmaceutical
- 8.15
- +0.15+1.88%
Jiangxi Fushine Pharmaceutical News
Fuxiang Pharmaceutical: Special Report on the Occupation of Non-operating Funds and Other Related Capital Transactions for the Semiannual Year of 2024
Fuxiang Pharmaceutical: Prompt Announcement on the Disclosure of the 2024 Semi-Annual Report
Jiangxi Fushine Pharmaceutical: Announcement regarding completion of industrial and commercial registration changes and issuance of new business license for subsidiary under control.
Jiangxi Fushine Pharmaceutical: Announcement regarding the acquisition of an invention patent certificate by a wholly-owned subsidiary.
Jiangxi Fushine Pharmaceutical: Announcement regarding the overseas listing of the company's invested companies.
Jiangxi Fushine Pharmaceutical: Announcement on the signing of the “Agreement on Termination of Special Shareholders' Rights”
Jiangxi Fushine Pharmaceutical: Notice on the holding subsidiary completing the registration of industrial and commercial changes and issuing a business license
Jiangxi Fushine Pharmaceutical: Announcement on the progress of the company's provision of guarantees to wholly-owned subsidiaries
Jiangxi Fushine Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Jiangxi Fushine Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Jiangxi Fushine Pharmaceutical: Announcement on Wholly-owned Subsidiaries Passing Pharmaceutical GMP Compliance Checks
Jiangxi Fushine Pharmaceutical: Announcement on preparation for impairment of long-term equity investments in subsidiaries
Jiangxi Fushine Pharmaceutical: Notice on using part of idle own funds for cash management
Jiangxi Fushine Pharmaceutical: Amendments to the Articles of Association (April 2024)
Jiangxi Fushine Pharmaceutical: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Jiangxi Fushine Pharmaceutical: Special report on the occupation of non-operating capital and other related capital transactions in 2023
Jiangxi Fushine Pharmaceutical: 2023 Financial Results Report
Jiangxi Fushine Pharmaceutical: 2024 First Quarter Report Disclosure Prompt Announcement
Jiangxi Fushine Pharmaceutical: Announcement on the launch of foreign exchange hedging business
Jiangxi Fushine Pharmaceutical: Accounting Services Selection and Hiring System
Analysis
Price Target
No Data
